Reclast (drug for menopause) – renal impairment Prempro/Premarin/Provera (drugs for menopause) – increased risk of breast cancer; strokes; heart attacks; cardiovascular disease; blood clots; urinary incontinence; cataracts; gout; joint degeneration; asthma; lupus; scleroderma; dementia; Alzheimer’s...
Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined...
Researchers at the University of Wisconsin-Madison School of Medicine and Public Health have eliminated cervical cancer in mice with two FDA-approved drugs currently used to treat breast cancer and osteoporosis. Published in this week's (Nov. 9)Proceedings of the National Academy of Sciences, the ...
Be tested for safety and efficacy on hundreds, possibly thousands of people in clinical trials Influence all-cause mortality Geroscience has a long way to go, but there are four FDA-approved drugs that have shown promise to “target the process of aging,” Barzilai says. While not approved as...
“new molecular entities” or “NMEs”. These drugs typically contain active moieties that have not previously been approved by the FDA. This list outlines the newmolecular entities(NMEs) and newtherapeutic biological productsapproved by the FDA’s Center for Drug Evaluation and Research (CDER) ...
Women’s and men’s health innovations that include a new treatment for osteoporosis in certain postmenopausal women at high risk of breaking a bone, a new drug to treat low sexual desire in premenopausal women, the first FDA-approved drug specifically for the treatment of adult women with post...
affect a patient's quality of life," said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "Xgeva has a different mechanism of action than currently approved drugs aimed at reducing bone complications from cancer."...
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of...
OFF-label use (Drugs)PHYSICIANSBackground: Teriparatide is approved for osteoporosis. Post-marketing surveillance is critical given its widespread use. Objective: To investigate adverse events (AEs) associated with teriparatide using the FAERS database, compare association strengt...
At a press conference today, Sandra Kweder, MD, deputy director of the Office of New Drugs in the agency's Center for Drug Evaluation and Research (CDER), said patients with osteoporosis who are taking a bisphosphonate should continue to do so unless advised by their healthcare provider not...